NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Enovis Corporation (ENOV) Stock Analysis

Enovis Corporation (ENOV) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

ENOV

$18.56

−$0.84 (−4.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENOV with… →

ENOV Key Statistics

As of Sep 4, 2026
Trading
Open
$19.01
Previous Close
$19.40
Day's Range
18.52–19.32
52-Week Range
18.52–34.28
Volume
1.89M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.43
Valuation
Market Cap
$1.07B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.03
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.45
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−19.27
Financials (FY)
Revenue (FY)
$2.25B+6.66%
Net Income (FY)
−$1.18B
Profit marginThe share of revenue left as profit after all costs and taxes.
−47.97%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.67M
1-Year Return
−41.17%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.22M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ENOV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−30.33%
2025−39.29%
2024−21.67%
2023+4.67%
2022−32.36%
2021+20.21%
2020+5.11%
2019+74.07%
2018−47.25%
2017+10.27%
2016 (partial year)+19.33%

As of September 4, 2026.

ENOV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.25B−$1.18B−52.7%
2024$2.11B−$825.49M−39.2%
2023$1.71B−$33.26M−1.9%
2022$1.56B−$13.29M−0.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.25B$1.35B−$18.87M−$1.18B−52.7%
2024$2.11B$1.18B−$103.43M−$825.49M−39.2%
2023$1.71B$990.78M−$48.37M−$33.26M−1.9%
2022$1.56B$869.38M−$90.66M−$13.29M−0.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ENOV Valuation vs Medical Devices Median

Median of 151 stocks
MetricENOVMedical Devices medianvs median
P/S ratio0.472.980.2x the median
Profit margin−47.97%−1.69%46.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Enovis Corporation (ENOV) at $1.07B. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 7,802 employees.

The 52-week range on file runs from $18.52 to $34.28. ENOV last closed at $18.56 on September 4, 2026. That is −$0.84 (−4.33%) against the previous close. The latest close sits 0.22% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.25B. Against the prior fiscal year total of $2.11B, that is a change of +6.66%. The same year closed with a net loss of $1.18B. The reported profit margin is −47.97%. That is 46.3 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −19.27.

Across the 4 fiscal years on file, revenue moves from $1.56B in 2022 to $2.25B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 5.03. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.45. Measured against sales, the shares trade at 0.47 times revenue. On price-to-sales that is 0.2 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −41.17%. Across 10 years the annualized return works out at −9.68%. The reported beta is 1.43. Daily returns over the trailing 10 years annualize to a volatility of 43.84%.

Growth & Income

The record shows no dividend for ENOV.

Across the complete calendar years on file, 2019 returned +74.07% and 2018 returned −47.25%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −30.33% year to date.

Peer Comparison

Enovis Corporation (ENOV) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Enovis Corporation ENOV $1.07B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Enovis Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Enovis Corporation

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Visit website →